CXCR2 inhibition enables NASH-HCC immunotherapy
J. Leslie, J. B. G. Mackey, T. Jamieson, E. Ramon-Gil, T. M. Drake, F. Fercoq, W. Clark, K. Gilroy, A. Hedley, C. Nixon, S. Luli, M. Laszczewska, R. Pinyol, R. Esteban-Fabro, C. E. Willoughby, , Carlin
This study shows that combining CXCR2 inhibition with anti-PD1 therapy enhances immunotherapy response in NASH-HCC by reprogramming tumor-associated neutrophils.
bioRxiv · Feb 24, 2022Cancer Biology